[1] European Association for the Study of the Liver . Electronic address eee, European Association for the Study of the L. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol, 2018, 69: 182-236.
[2] Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology, 2018; 67: 358-380.
[3] Omata M, Cheng AL, Kokudo N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int, 2017, 11: 317-370.
[4] Chang TS, Wu YC, Tung SY, et al. Alpha-Fetoprotein Measurement Benefits Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis. AmJ Gastroenterol, 2015, 110: 836-844 quiz 845.
[5] Zhang B, Yang B. Combined alpha fetoprotein testing and ultrasonography as a screening test for primary liver cancer. J Med Screen, 1999, 6: 108-110.
[6] Feng M, Suresh K, Schipper MJ, et al. Individualized adaptive stereotactic body radiotherapy for liver tumors in patients at high risk for liver damage: a phase 2 clinical trial. JAMA Oncol, 2018, 4: 40-47.
[7] Yoon SM, RYoo BY, Lee SJ, et al. Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion: a randomized clinical trial. JAMA Oncol, 2018, 4: 661-669.
[8] Radiation Therapy Oncology Group . RTOG 1112: Sorafenib tosylate with or without stereotactic body radiation therapy in treating patients with liver cancer. Available at: https://clinicaltrials.gov/ct2/show/NCT01730937
[9] Palma DA, Olson RA, Harrow S, et al. Stereotactic ablative radiation therapy for the comprehensive treatment of oligometastatic tumors (SABR-COMET): results of a randomized trial. Int J Radiat Oncol, 2019, 102: S3-S4. |
